Can digestive enzymes help IBS and bloating?
The studies cited here do not establish a general enzyme treatment for IBS. They tested specific formulations and selected populations; some overall results were negative or nonsignificant, and some favorable findings came from subgroups or uncontrolled reports.
Quick answer
What the documentation supports
- The child alpha-galactosidase trial reported improvement in some gas-related outcomes; the acute adult IBS trial found no superiority to placebo. The child trial was not a general IBS treatment trial.
- The pancrelipase pilot had a nonsignificant overall intention-to-treat preference result; favorable symptom findings came from the subgroup who chose enzymes. This does not demonstrate a benefit for all IBS-D participants.
- One controlled study of a soluble-fiber-plus-enzyme combination for bloating and abdominal pain — a combination product, so the effect can't be attributed to the enzymes alone.
- One 2026 real-world survey of a FODMAP-targeting enzyme blend reporting improvement in bloating and other symptoms — an uncontrolled pre-post cohort, not a randomized trial, so it cannot establish that the enzyme caused the improvement.
What it does not support
- Treating any broad retail enzyme blend as an established treatment for IBS based on the specific studies cited here.
- A best-enzyme-for-IBS ranking or an assumption of equal benefit from different formulations.
Is an over-the-counter product relevant here?
The cited evidence is formulation- and population-specific; it does not establish interchangeable effects for broad retail blends or replace medical assessment of IBS.
What research actually exists
NIDDK describes IBS as a disorder of gut–brain interaction, with multiple possible contributing factors and varying bowel patterns. The enzyme studies cited here do not establish a general treatment for the syndrome; a food-substrate mechanism is not itself proof of clinical benefit.
The cited studies differ substantially: child and adult alpha-galactosidase trials have mixed results; the pancrelipase pilot’s overall enzyme-preference comparison did not reach statistical significance, while a selected subgroup had symptom improvements; a beta-glucan/inositol/enzyme combination study reported some changes but cannot isolate the enzyme contribution; and a 2026 uncontrolled customer cohort reported improvement with a FODMAP-targeting blend. These are not interchangeable products or evidence of a general IBS cure.
Why each of these falls short of proving a general fix
Money et al. randomized 49 participants, with 39 completing the crossover. The overall intention-to-treat enzyme-versus-placebo preference comparison did not reach statistical significance (p=0.078). Favorable detailed symptom analyses were reported in the 25 completers who chose enzymes, which requires subgroup and attrition context.
Ciacci et al. tested beta-glucan, inositol and digestive enzymes against a no-treatment comparison over four weeks. The combination design cannot separate an enzyme effect; a no-treatment comparison is not a blinded placebo-controlled comparison.
Kaye et al. reported an uncontrolled customer cohort: 1,075 completed baseline, 349 completed follow-up and 118 entered the final analysis. This substantial attrition, self-selection and self-reported assessment limit interpretation. There was no placebo group or randomization, so improvement cannot be attributed causally to the blend. Kiwi Biosciences funded the project and data collection; some authors were company employees or a shareholder.
- IBS itself should be diagnosed by a clinician — this page does not diagnose it.
- Formulation, allergies, medical history and product warnings matter; the studies summarized here do not establish universal supplement safety.
Sources: Money et al., "Pilot study: a randomised, double blind, placebo controlled trial of pancrealipase for the treatment of postprandial irritable bowel syndrome-diarrhoea" — PMC3009417; Axcan supplied enzymes and supported statistical analysis and initial editing, without a role in planning or conduct; "Effect of beta-glucan, inositol and digestive enzymes in GI symptoms of patients with IBS" — PubMed 21796867; Kaye et al., "FODMAP-Targeting Digestive Enzyme Blend for Management of Gastrointestinal Symptoms: A 'Real-World' Pre-Post Intervention Cohort Study", Gastro Hep Advances (2026) — PubMed 41908325; funded by Kiwi Biosciences, with company-affiliated authors; Ciacci et al. — original full 2011 article, pages 637–643; NIDDK — IBS Definition & Facts; NIDDK — IBS Symptoms & Causes; Di Nardo et al. — child gas-symptom trial, not a general IBS trial; Böhn et al. — acute adult IBS crossover trial; supported by an unrestricted Oy Verman grant and public/foundation grants; company supplied randomization, otherwise not planning or conduct; author disclosures in the original. Last reviewed: July 29, 2026.